Form 4: IDEAYA Biosciences Director Terry J. Rosen Granted 20,000 Stock Options Under 10b5-1 Plan

IDEAYA Biosciences, Inc. Director Terry J. Rosen was granted 20,000 stock options with an exercise price of $21.78, vesting over the next year, as disclosed in a recent SEC Form 4 filing.

Summary

• Terry J. Rosen, a Director of IDEAYA Biosciences, Inc. (IDYA), was granted 20,000 stock options.
• The options have an exercise price of $21.78 per share.
• The grant date for the transaction was June 24, 2025.
• The options are set to expire on June 24, 2035.
• 100% of the shares subject to the option will vest on the earlier of the first anniversary of the grant date or immediately prior to the Annual Meeting following the grant date, contingent on continued service on the Board.
• The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged trading strategy.
• Following this transaction, Mr. Rosen beneficially owns 20,000 derivative securities directly.

Sentiment

Score: 5

Explanation: The document is a routine SEC Form 4 filing reporting a director's stock option grant. It contains factual information about a compensation event and does not inherently convey positive or negative sentiment regarding the company's operational or financial performance.

Positives

• The grant of stock options aligns the director's interests with those of shareholders, incentivizing long-term performance and value creation.
• The transaction was made pursuant to a Rule 10b5-1(c) plan, which demonstrates a pre-arranged and transparent approach to insider trading.

Future Outlook

The stock options granted to Director Terry J. Rosen are subject to a vesting schedule, with 100% of the shares vesting on the earlier of the first anniversary of the grant date (June 24, 2026) or immediately prior to the Annual Meeting following the grant date, contingent on his continued service on the Board.

Industry Context

The granting of stock options to directors is a common practice in the biotechnology and pharmaceutical industry, serving as a key component of executive and director compensation packages to attract and retain talent, and to align their long-term interests with shareholder value creation.

Related Party Transactions

• The grant of stock options to Terry J. Rosen, a Director, constitutes a related party transaction as it involves compensation to a member of the company's board.

Stakeholder Impact

• Shareholders: The grant aligns the director's interests with shareholders by incentivizing long-term stock performance. It represents a potential future dilution if options are exercised, but is a standard part of director compensation.

Next Steps

• Continued service of Terry J. Rosen on the Board of Directors for the options to vest.
• Vesting of 20,000 stock options on the earlier of June 24, 2026, or immediately prior to the Annual Meeting following the grant date.

Key Dates

Keywords

IDEAYA Biosciences, IDYA, SEC Form 4, Stock Options, Director Compensation, Terry J. Rosen, Equity Grant, Insider Transaction, Rule 10b5-1